Germany · Delayed Price · Currency is EUR Agios Pharmaceuticals Statistics
Total Valuation
FRA:8AP has a market cap or net worth of EUR 1.40 billion. The enterprise value is 353.34 million.
| Market Cap | 1.40B |
| Enterprise Value | 353.34M |
Important Dates
The next estimated earnings date is Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 58.31M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 1.68% |
| Owned by Institutions (%) | 99.69% |
| Float | 51.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.58 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.03 |
| EV / Sales | 9.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.00 |
Financial Position
The company has a current ratio of 13.82, with a Debt / Equity ratio of 0.03.
| Current Ratio | 13.82 |
| Quick Ratio | 12.81 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.57% and return on invested capital (ROIC) is -19.71%.
| Return on Equity (ROE) | -27.57% |
| Return on Assets (ROA) | -18.71% |
| Return on Invested Capital (ROIC) | -19.71% |
| Return on Capital Employed (ROCE) | -36.28% |
| Revenue Per Employee | 78,389 |
| Profits Per Employee | -702,255 |
| Employee Count | 488 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 11.63 |
Taxes
| Income Tax | -7.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.32% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -55.32% |
| 50-Day Moving Average | 33.07 |
| 200-Day Moving Average | 30.25 |
| Relative Strength Index (RSI) | 36.93 |
| Average Volume (20 Days) | 5 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.63 |
Income Statement
In the last 12 months, FRA:8AP had revenue of EUR 38.18 million and -342.00 million in losses. Loss per share was -5.93.
| Revenue | 38.18M |
| Gross Profit | -251.62M |
| Operating Income | -405.35M |
| Pretax Income | -349.56M |
| Net Income | -342.00M |
| EBITDA | -400.85M |
| EBIT | -405.35M |
| Loss Per Share | -5.93 |
Balance Sheet
The company has 812.12 million in cash and 37.94 million in debt, giving a net cash position of 1.03 billion.
| Cash & Cash Equivalents | 812.12M |
| Total Debt | 37.94M |
| Net Cash | 1.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.09B |
| Book Value Per Share | 18.78 |
| Working Capital | 816.80M |
Cash Flow
In the last 12 months, operating cash flow was -349.38 million and capital expenditures -3.55 million, giving a free cash flow of -352.93 million.
| Operating Cash Flow | -349.38M |
| Capital Expenditures | -3.55M |
| Free Cash Flow | -352.93M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,061.80% |
| Pretax Margin | -915.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:8AP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | -24.49% |
| FCF Yield | -25.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:8AP has an Altman Z-Score of 11.9 and a Piotroski F-Score of 3.
| Altman Z-Score | 11.9 |
| Piotroski F-Score | 3 |